Insights into significant pathways and gene interaction networks in peripheral blood mononuclear cells for early diagnosis of hepatocellular carcinoma

Jiang, Jian; Yu, Chao; Li, Zhi Peng; Xiao, Jie; Zhang, Hao; Chen, Mei Yuan; Sun, Cheng Yi

doi:10.4103/0973-1482.154081

Cited by 14 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our current study, we found HER2 gene amplification was related to bowel wall invasion and advanced tumor stage, but several other studies have failed to show such relationship. Li et al (2011b) reported an association between HER2 expression and tumor size and distant metastases, and a recent meta-analysis showed HER2 amplification was associated with lymph node metastasis and advanced tumors stage (Sun et al, 2016). The number of studies suggests that HER2 may play some role in tumor progression and would be a valuable prognostic factor for CRC patients (Laurentpuig et al, 2016;Stahler et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China

Zhang

Wang

et al. 2020

PeerJ

View full text Add to dashboard Cite

Objective To investigate the frequency and prognostic role of the human epidermal growth factor receptor 2 gene (HER2) and BRAF V600E gene mutation in Chinese patients with colorectal cancer (CRC). Methods Clinicopathological and survival information from 480 patients with stage I–III CRC were reviewed and recorded. HER2 amplification was analyzed by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), BRAF V600E mutation was tested by IHC and Sanger sequencing. The relationship between HER2 and BRAF V600E mutation status and clinicopathological characteristics and outcomes were determined. Results The amplification of HER2 and BRAF V600E mutation were identified in 27 of 480 (5.63%) and 19 of 480 (3.96%) CRC patients, respectively. HER2 amplification significantly correlated with greater bowel wall invasion (P = 0.041) and more advanced TNM stage (I vs. II vs. III; 0 vs 5.78% vs. 7.41%, P = 0.013). Patients suffering from tumors with poor differentiation had a higher incidence rate of BRAF V600E mutation than those with moderate/well differentiation (7.77% vs 2.92%, P = 0.04). HER2 amplification was an independent prognostic factor for worse disease-free survival (DFS) (HR = 2.53, 95% CI: 1.21–5.30, P = 0.014). Conclusion The prevalence of HER2 amplification and BRAF V600E mutation in stage I–III CRC patients in Chinese was 6% and 4%, respectively, and HER2 amplification appeared to be associated with a worse DFS. More comprehensive molecular classification and survival analysis are needed to validate our findings.

show abstract

Section: Discussionmentioning

confidence: 99%

HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China

Zhang

Wang

et al. 2020

PeerJ

View full text Add to dashboard Cite

show abstract

“…Due to a large number of lymphoma subtypes, some genes may show consistent differential expression in multiple lymphoma subtypes that may interfere with the diagnostic specificity. Furthermore, complex gene-gene interactions also affect the accuracy of tumor diagnosis [ 21 ] and prognostic status [ 22 ]. Therefore, a diagnostic model with excellent performance should also be robust and hardly affected by gene-gene interactions.…”

Section: Introductionmentioning

confidence: 99%

Transcriptome integration analysis and specific diagnosis model construction for Hodgkin's lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma

Dai

et al. 2021

Aging

View full text Add to dashboard Cite

Transcriptome differences between Hodgkin's lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL), which are all derived from B cell, remained unclear. This study aimed to construct lymphoma-specific diagnostic models by screening lymphoma marker genes. Transcriptome data of HL, DLBCL, and MCL were obtained from public databases. Lymphoma marker genes were screened by comparing cases and controls as well as the intergroup differences among lymphomas. A total of 9 HL marker genes, 7 DLBCL marker genes, and 4 MCL marker genes were screened in this study. Most HL marker genes were upregulated, whereas DLBCL and MCL marker genes were downregulated compared to controls. The optimal HL-specific diagnostic model contains one marker gene (MYH2) with an AUC of 0.901. The optimal DLBCL-specific diagnostic model contains 7 marker genes (LIPF, CCDC144B, PRO2964, PHF1, SFTPA2, NTS, and HP) with an AUC of 0.951. The optimal MCL-specific diagnostic model contains 3 marker genes (IGLV3-19, IGKV4-1, and PRB3) with an AUC of 0.843. The present study reveals the transcriptome data-based differences between HL, DLBCL, and MCL, when combined with other clinical markers, may help the clinical diagnosis and prognosis.

show abstract

“…9 Also, there are experiments utilizing the gene expression on peripheral white blood cells to detect these cancer's in uences. [10][11][12][13][14] Therefore, an invention of markers that are inexpensive, simple, less-invasive and highly accurate can be expected. We focused on the usability of peripheral white blood cells (WBCs), especially peripheral blood mononuclear cells (PBMCs) as a biomarker for liver cancers.…”

Section: Introductionmentioning

confidence: 99%

The Expression of FLNA and CLU in PBMCs As A Novel Screening Marker for Hepatocellular Carcinoma.

Patarat

Riku

Kunadirek

et al. 2021

Preprint

View full text Add to dashboard Cite

Early detection improves survival and increases curative probability in hepatocellular carcinoma (HCC). Peripheral blood mononuclear cells (PBMCs) can provide an inexpensive, less-invasive and highly accurate method. The objective of this study is to find the potential marker for HCC screening, utilizing gene expression of the PBMCs. Data from the NCBI GEO database of gene expression in HCC patients and healthy donor's PBMCs was collected. As a result, GSE 49515 and GSE 58208 were found. Using both, a statistical significance test was conducted in each gene expression of each data set which resulted in 187 genes. We randomized three selected genes (FLNA, CAP1, and CLU) from the significant p-value group (p-values < 0.001). Then, a total of 76 healthy donors and 153 HCC cases were collected. Quantitative RT-PCR (qRT-PCR) was performed in cDNA from all blood samplesFrom the qRT-PCR, The Cycle threshold (Ct) value of FLNA, CLU, CAP1 of HCC group (28.47±4.43, 28.01±3.75, 29.64±3.90) were lower than healthy group (34.23±3.54, 32.90±4.15, 32.18±5.02) (p-values < 0.0001). The accuracy, sensitivity and specificity of these genes as a screening tool were: FLNA (80.8%, 88.0%, 65.8%), CLU (63.4%, 93.3%, 31.3%), CAP1 (67.2%, 83.3%, 39.1%). The tests were performed in two and three gene combinations. Results demonstrated high accuracy of 86.2%, sensitivity of 85% and specificity of 88.4% in the FLNA and CLU combination. We concluded that FLNA and CLU combination have high potential for being HCC novel markers. Combined with current tumor markers, further research of the gene’s expression might help identify more potential markers and improve diagnosis methods.

show abstract

Insights into significant pathways and gene interaction networks in peripheral blood mononuclear cells for early diagnosis of hepatocellular carcinoma

Cited by 14 publications

References 0 publications

HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China

HER2 and BRAF mutation in colorectal cancer patients: a retrospective study in Eastern China

Transcriptome integration analysis and specific diagnosis model construction for Hodgkin's lymphoma, diffuse large B-cell lymphoma, and mantle cell lymphoma

The Expression of FLNA and CLU in PBMCs As A Novel Screening Marker for Hepatocellular Carcinoma.

Contact Info

Product

Resources

About